A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) saw some unusual options trading on Tuesday. Traders acquired 46,473 call options on the company. This represents an increase of approximately 61% ...
Bristol-Myers Squibb saw an unexpected spike in options trading, with call options increasing by 61% compared to the average.
Shares of Bristol Myers Squibb Co. BMY slid 1.43% to $57.38 Wednesday, on what proved to be an all-around mixed trading ...
We recently published a list of Dividend Stock Portfolio For Income: Top 10 Stocks to Buy. In this article, we are going to ...
Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...
The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...
In other words, for those looking for "forever stocks," it's not a bad idea to look in this sector. And even with a modest ...
1d
Medpage Today on MSNNovel Drug Shrinks 73% of HER2-Mutant Lung Cancers"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically ...
Just take a look at the healthcare sector. By all accounts, healthcare stocks should be in the dumps. The sector sold off ...
William Blair analysts have lowered their FY2027 earnings per share estimate for Bristol-Myers Squibb from $7.70 to $6.50.
This was the stock's fifth consecutive day of gains.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results